Skip to main content
Premium Trial:

Request an Annual Quote

Silence Receives Notice of Allowance for US Patent Application

Premium

Silence Therapeutics said this week that it has received a notice of allowance from the US Patent and Trademark Office on a patent application covering its siRNA delivery technology.

According to Silence, the allowed claims relate to the company's AtuPlex technology. Specifically, they cover the proprietary lipid used in the delivery system. The company noted that the technology is being used in its phase I cancer drug Atu027, as well as certain other RNAi drug candidates.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.